Company Overview - Vaxcyte is a clinical-stage biotechnology company focused on developing next-generation protein vaccines to meet unmet medical needs in bacterial infectious disease prevention [2] - The company's pipeline includes vaccines such as VAX-24 for pneumococcal disease, VAX-XP for emerging strains, VAX-A1 for Group A Strep, and VAX-PG for periodontitis [1][2] - Vaxcyte employs advanced conjugation and protein engineering technologies to enhance vaccine coverage and combat antibiotic resistance [2] Recent Insider Activity - Harpreet S. Dhaliwal, Chief Technical Ops Officer of Vaxcyte, sold 9,743 shares in an open-market transaction valued at approximately $454,891, reducing his direct ownership by 28.9% [4][5] - Following this sale, Dhaliwal's stake decreased from 33,671 shares to 23,928 shares, with no remaining indirect exposure [3][4] Stock Performance - Vaxcyte's stock price has declined by 44.2% over the past year, contrasting with an 18.4% return from the S&P 500 index during the same period [5] - The company's shares experienced a significant drop in late March and early April, followed by a modest recovery, which raises concerns about the sustainability of this momentum [6] Financial Performance - Vaxcyte does not have any approved products on the market, resulting in no revenue generation [6] - The company reported a loss of $520.1 million during the first nine months of 2025 [6] Future Outlook - Monitoring the approval process for Vaxcyte's vaccines will be crucial for assessing the company's future success [7] - Insider transactions, such as those by Dhaliwal, may provide insights into the confidence of company leadership regarding product approvals [7]

Vaxcyte keeps its place among Mizuho Securities top picks entering 2026. ...

Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50. On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with a target price of $85. This results in an upside of over 83% from the current level. Sharder mentioned the positive results from Phase 2 trials for the VAX-31 vaccine, which will prove to be a building block for the critical Phase 3 trials. The upcoming trial’s robust d ...

The pneumococcal vaccine market has been dominated for years by large companies using conventional conjugate chemistry methods that are effective; however, there exists a biological ceiling known as "carrier suppression" which limits how far traditional conjugate chemistries canI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinking enterprises. My a ...

Core Insights - The pneumococcal vaccine market has been historically dominated by large companies utilizing conventional conjugate chemistry methods, which are effective but face limitations due to a phenomenon known as "carrier suppression" [1] Group 1: Market Dynamics - The traditional conjugate chemistries in the pneumococcal vaccine market have reached a biological ceiling, indicating a need for innovation to overcome these limitations [1] Group 2: Investment Perspective - There is a strong inclination towards high-growth companies in sectors that are expected to experience exponential expansion, highlighting the potential for disruptive technologies and forward-thinking enterprises [1]

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks to buy, according to Wall Street analysts. On December 8, the company confirmed the dosing of the first patients in its Phase 3 OPUS trial. The company is evaluating VAX-31 in the prevention of invasive pneumococcal disease and pneumonia in adults. It plans to enroll 4,000 participants in consultation with the US Food and Drug Administration. Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension Topline safety and ...

Core Insights - The article discusses the initiation of the OPUS Phase 3 trial for VAX-31, a new pneumococcal conjugate vaccine aimed at improving protection against invasive pneumococcal disease (IPD) and pneumonia in adults [2][5][12] Trial Design and Objectives - The OPUS trial is a pivotal, noninferiority study designed to evaluate the safety, tolerability, and immunogenicity of VAX-31 compared to current standard-of-care vaccines, PCV21 and PCV20 [2][3] - Approximately 4,000 participants will be enrolled, with topline results expected in Q4 2026, which will support a Biologics License Application (BLA) submission [2][5] - The primary immunogenicity objectives include demonstrating noninferiority and superiority of VAX-31 against the comparator vaccines for various serotypes [4][9] Vaccine Coverage and Efficacy - VAX-31 is designed to cover approximately 95% of IPD and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, with potential increases in coverage of 14-34% for IPD and 19-31% for pneumonia compared to existing vaccines [13][14] - The vaccine aims to maintain pressure on both currently circulating and historically significant serotypes, enhancing immune responses [2][6] Company Background and Technology - Vaxcyte, the company behind VAX-31, focuses on vaccine innovation and utilizes a carrier-sparing, site-specific conjugation technology to enhance vaccine efficacy [16][17] - The company is also developing other vaccine candidates, including VAX-24 for infants, which aims to cover more serotypes than any current infant PCV on the market [16][12] Anticipated Milestones - Key upcoming milestones include the announcement of topline data from the OPUS trial in Q4 2026 and the initiation of additional Phase 3 studies in 2026, with results expected in 2027 [10][15]

Vaxcyte (NasdaqGS:PCVX) FY Conference December 02, 2025 01:20 PM ET Company ParticipantsJames Wassil - COOAndrew Guggenhime - President and CFOModeratorSo, Andrew, I woke up Saturday and I had a text message from Vinay. I'm like, Vinay's texting me. What is going on? And I realized I was on some email chain. So I started reading it, and that's when I shot you an email on Saturday morning. Wow, what's going on here? So let's just start. Where are things standing on FDA? Because I feel like that's probably th ...

Core Insights - Shares of major vaccine manufacturers including Moderna, BioNTech, Pfizer, Novavax, and Vaxcyte experienced declines following the FDA's announcement of new stringent vaccine requirements [1][7] Regulatory Changes - Dr. Vinay Prasad, head of the FDA's CBER, acknowledged in an internal memo that "COVID-19 vaccines have killed American children," citing at least 10 child deaths linked to COVID-19 vaccinations and myocarditis concerns [2][3] - The FDA plans to revise guidelines for various vaccines, including stricter safety requirements for vaccines administered to pregnant women and a reevaluation of the annual influenza vaccine framework [4][5] Market Reaction - Following the news, Moderna's shares fell by 7%, BioNTech by 6%, Pfizer by nearly 2%, Novavax by 5%, and Vaxcyte by over 8% [7] - Investor concerns are heightened regarding the potential for increased anti-vaccine sentiment due to the FDA's stricter regulatory focus [8] Industry Context - The developments align with the current leadership at the Department of Health and Human Services under Robert F. Kennedy Jr., known for his skepticism towards vaccines, raising questions about the independence of public health decision-making [9][11] - The upcoming CDC advisory committee meeting scheduled for December 4-5, 2025, will discuss the childhood vaccine schedule and hepatitis B shot, adding further pressure on vaccine manufacturers [8]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...